References
- Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J (2003). Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 12, 872-5.
- Aghakhani A, Hamkar R, Parvin M, et al (2011). The role of Human papillomavirus infection in prostate carcinoma. Scand J Infect Dis, 43, 64-9. https://doi.org/10.3109/00365548.2010.502904
- Anwar K, Nakakuki K, Shiraishi T, et al (1992). Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res, 52, 5991-6.
- Araujo-Neto AP, Ferreira-Fernandes H, Amaral CM, et al (2016). Lack of detection of human papillomavirus DNA in prostate carcinomas in patients from northeastern Brazil. Genet Mol Biol, 39, 24-9. https://doi.org/10.1590/1678-4685-GMB-2015-0122
- Atashafrooz F, Rokhbakhsh-Zamin F (2016). Frequency and type distribution of human papilloma virus in patients with prostate cancer, kerman, southeast of Iran. Asian Pac J Cancer Prev, 17 , 3953-8
- Carozzi F, Lombardi FC, Zendron P, et al (2004). Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers, 19, 257-61. https://doi.org/10.5301/JBM.2008.3977
- Choo CK, Ling MT, Chan KW, et al (1999). Immortalization of human prostate epithe¬lial cells by HPV 16 E6/E7 open reading frames. Prostate, 40, 150-8. https://doi.org/10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7
- Dell G, Gaston K (2001). Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci, 58, 1923-42. https://doi.org/10.1007/PL00000827
- Ghasemian E, Monavari SH, Irajian GR, et al (2013). Evaluation of human papillomavirus infections in prostatic disease: a cross-sectional study in Iran. Asian Pac J Cancer Prev, 14, 3305-8. https://doi.org/10.7314/APJCP.2013.14.5.3305
- Hrbacek J, Urban M, Hamsikova E, et al (2011). Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer, 11, 53. https://doi.org/10.1186/1471-2407-11-53
- Lazcano-Ponce E (2001). High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. STD, 28, 277-80. https://doi.org/10.1097/00007435-200105000-00007
- Marklund L, Hammarstedt L (2011). Impact of HPV in oropharyngeal cancer. J Oncol, 10, 509036.
- Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, et al (2010). Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer, 10, 326-30. https://doi.org/10.1186/1471-2407-10-326
- McNicol PJ, Dodd JG (1990). Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol, 28, 409-12.
- Medeiros F, Rigl CT, Anderson GG Becker SH, Halling KC (2007). Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch Pathol Lab Med, 131, 1805-16.
- Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U (1999). Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers.Cancer Res, 59, 823-5.
- Sfanos KS, Isaacs WB, De Marzo AM (2013). Infections and inflammation in prostate cancer. Am J Clin Exp Urol, 25, 3-11.
- Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
- Strickler HD, Burk R, Shah K, et al (1998). A multifaceted study of human papillomavirus and prostate carcinoma. Cancer, 82, 1118-25. https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9
- Yang L, Xie S, Feng X, et al (2015). Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis. Sci Rep, 5, 14667. https://doi.org/10.1038/srep14667